vidarabine has been researched along with Hematologic Diseases in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.27) | 18.7374 |
| 1990's | 2 (4.55) | 18.2507 |
| 2000's | 24 (54.55) | 29.6817 |
| 2010's | 16 (36.36) | 24.3611 |
| 2020's | 1 (2.27) | 2.80 |
| Authors | Studies |
|---|---|
| Araqi Houssaini, L; Chiheb, S; Hali, F; Marnissi, F; Quessar, A | 1 |
| Catakovic, K; Egle, A; Gassner, FJ; Geisberger, R; Girschikofsky, M; Greil, R; Hartmann, TN; Lang, A; Melchardt, T; Petzer, A; Pleyer, L; Steurer, M; Thaler, J; Voskova, D; Weiss, L; Zaborsky, N | 1 |
| Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D | 1 |
| Chambellan, A; Chevallier, P; Delasalle, B; Delaunay, J; Dirou, S; Germaud, P; Guillaume, T; Lemarchand, P; Malard, F; Mohty, M; Moreau, P | 1 |
| Araoka, H; Asano-Mori, Y; Hayashi, M; Ishiwata, K; Ito, T; Izutsu, K; Kaji, D; Makino, S; Masuoka, K; Matsuno, N; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Uchida, Y; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A | 1 |
| Abedin, S; Choi, S; Couriel, DR; Levine, JE; Peres, E; Yanik, G | 1 |
| Chen, T; Du, Q; Huang, Y; Lin, X; Lu, Z; Song, C; Sun, C; Tao, Y; Tu, S; Wu, B | 1 |
| Araoka, H; Asano-Mori, Y; Ikebe, T; Ishiwata, K; Izutsu, K; Kon, A; Makino, S; Masuoka, K; Matsuno, N; Nakano, N; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A | 1 |
| Aljurf, MD; Arat, M; Bader, P; Boelens, JJ; Duarte, R; Faraci, M; Lawitschka, A; Peters, C; Socie, G; Tichelli, A; Veys, P; Wachowiak, J; Yaniv, I | 1 |
| Iida, S; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Masaki, A; Masuda, A; Narita, T; Ri, M; Totani, H; Yoshida, T | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Carney, D; Gill, S; Januszewicz, H; Prince, HM; Ritchie, D; Seymour, JF; Westerman, D; Wolf, M | 1 |
| Bruns, I; Czibere, A; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Zohren, F | 1 |
| Baldini, L; Cortelezzi, A; Gritti, G; Maura, F; Molica, S; Neri, A; Piciocchi, A; Reda, G | 1 |
| Eshkar-Sebban, L; Gellman, YN; Lytton, SD; Nagler, A; Naor, D; Or, R; Refaeli, E; Rosenblum, N; Shimoni, A; Shimony, O; Stanevsky, A; Yerushalmi, R | 1 |
| Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Esterni, B; Fürst, S; Granata, A; Oudin, C; Vey, N | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Casadei, B; Celli, M; Derenzini, E; Fanti, S; Gandolfi, L; Pellegrini, C; Pileri, S; Poletti, V; Quirini, F; Stefoni, V; Zinzani, PL | 1 |
| Chao, NJ; Clay, TM; Hobeika, AC; Lyerly, HK; Morse, MA; Mosca, PJ; Rizzieri, D; Stenzel, TT; Vredenburgh, JJ | 1 |
| Darbyshire, PJ; Kinning, E; Ortín, M; Raj, R; Williams, M | 1 |
| Anasetti, C; Blume, KG; Chauncey, T; Deininger, M; Hegenbart, U; Lange, T; Little, MT; Maloney, DG; Maris, M; McSweeney, PA; Niederwieser, D; Petersdorf, E; Pönisch, W; Sandmaier, BM; Shizuru, JA; Storb, RF; Storer, B; Woolfrey, A | 1 |
| Ayala, A; Cabanillas, F; Hagemeister, FB; Hess, M; Lee, MS; McLaughlin, P; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, TL; Tsimberidou, AM; Yang, Y; Younes, A | 1 |
| Bar, M; Cohen, NS; del Prete, S; Flamm, M; Garrett, TJ; Heitjan, D; Hesdorffer, CS; Lonberg, M; March, R; Mears, JG; Nichols, G; Oster, MW; Savage, DG; Talbot, S; Taub, RN | 1 |
| Burrows, A; Edenfield, WJ; Ekstrand, J; Lucas, M; Myhand, RC; Nelson, DA; Waselenko, JK | 1 |
| Aymerich, M; Carreras, E; Fernández-Avilés, F; Jiménez, M; Martínez, C; Montserrat, E; Rovira, M; Talarn, C; Urbano-Ispizua, A | 1 |
| Fu, ZZ; Li, CX; Lin, BJ; Liu, YJ; Ma, X; Miao, M; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xia, XM | 1 |
| Ai, HS; Guo, M; Qiao, JH; Shi, BF; Sun, QY; Sun, WJ; Wang, DH; Yao, B; Yu, CL; Zhang, S | 1 |
| Hamaki, T; Heike, Y; Hori, A; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Kusumi, E; Masuo, S; Miyakoshi, S; Mori, S; Morinaga, S; Murashige, N; Muto, Y; Takaue, Y; Taniguchi, S; Tanosaki, R; Ueyama, J; Yuji, K | 1 |
| Anastasi, J; Larson, R; Odenike, T; Smith, S; Stock, W; Thirman, M; Van Besien, K | 1 |
| Hamaki, T; Hayashi, T; Kami, M; Kanemaru, M; Kim, SW; Kishi, Y; Kobayashi, K; Kusumi, E; Masuo, S; Miyakoshi, S; Mori, S; Morinaga, S; Murashige, N; Muto, Y; Takaue, Y; Taniguchi, S; Ueyama, J; Yuji, K | 1 |
| Boyd, RL; Clyde, J; Halbherr, T; Millenson, MM; Morris, GJ; Padavic-Shaller, K; Rogatko, A; Schilder, RJ; Smith, MR; Wang, H; Yeslow, G | 1 |
| Blumstein, N; Buchmann, I; Buck, AK; Bunjes, D; Döhner, H; Glatting, G; Kotzerke, J; Neumaier, B; Reske, SN; Ringhoffer, M; Schauwecker, P; Stilgenbauer, S; von Harsdorf, S; Wiesneth, M; Zenz, T | 1 |
| Baxter-Lowe, LA; Cowan, M; Desantes, K; Englert, L; Horn, B; McMillan, A; Quinn, M | 1 |
| Taniguchi, S | 1 |
| Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K | 1 |
| Blau, IW; Blau, O; Göldner, H; Hopfenmüller, W; Knauf, W; Leschinger, N; Schmidt-Hieber, M; Thiel, E | 1 |
| Appelbaum, FR; Bedalov, A; Bryant, EM; Chang, C; Clurman, BE; Deeg, HJ; Flowers, ME; Hansen, JA; Nash, RA; Sanders, JE; Sandmaier, BM; Scott, BL; Shulman, HM; Storb, R; Storer, BE; Witherspoon, RP | 1 |
| Bhatia, R; Chang, K; Forman, SJ; Kirschbaum, M; Kogut, N; Naing, A; Nakamura, R; O'Donnell, MR; Palmer, J; Pullarkat, V; Rodriguez, R; Slovak, ML; Spielberger, R; Stein, A; Tsai, N | 1 |
| Lyon, RA; Swigart, S | 1 |
| Alcala, A; Arias-Sampedro, J; Bosch, F; Fernandez, MN; Garcia-Conde, J; Guardia, R; Lopez-Lorenzo, JL; Manso, F; Martin, A; Montserrat, E; Odriozola, J; Oyarzabal, FJ; Prieto, E | 1 |
| Cusack, JC; Keating, MJ; Lerner, S; Pollock, RE; Seymour, JF | 1 |
| Carella, AM; Giralt, S; Slavin, S | 1 |
| Balzarotti, M; Bonadonna, G; De Paoli, A; Luoni, M; Rampinelli, I; Santoro, A; Tondini, C; Valagussa, P | 1 |
| Abonour, R; Kim, K; Longo, WL; Mosher, DF; Turman, NJ; Vidarsson, B; Wiersma, SR; Williams, EC; Woodson, RD | 1 |
3 review(s) available for vidarabine and Hematologic Diseases
| Article | Year |
|---|---|
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
[Reduced-intensity cord blood transplantation for adult hematological diseases].
Topics: Adult; Age Factors; Antigens, CD34; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Diseases; Hematologic Neoplasms; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine | 2006 |
Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia.
Topics: Antineoplastic Agents; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2000 |
12 trial(s) available for vidarabine and Hematologic Diseases
| Article | Year |
|---|---|
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Consolidation Chemotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Hematologic Diseases; Humans; Immunity, Cellular; Immunologic Memory; Immunotherapy; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction; Rituximab; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Vidarabine | 2018 |
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2013 |
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Pilot Projects; Survival Rate; Time Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2014 |
Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Cytomegalovirus; Cytomegalovirus Infections; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Salvage Therapy; Vidarabine; Virus Activation | 2012 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2012 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2002 |
Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Follow-Up Studies; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2003 |
Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity.
Topics: Adult; Antigens, CD34; Cyclophosphamide; Female; Hematologic Diseases; Hematologic Neoplasms; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutrophils; Peripheral Blood Stem Cell Transplantation; Platelet Count; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Rate; Vidarabine | 2003 |
Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Interferon alpha-2; Interferon-alpha; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Topics: Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Antilymphocyte Serum; Antineoplastic Agents; Cell Adhesion Molecules; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Leukemia; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Radioisotopes; Radiometry; Rhenium; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2005 |
Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Disease-Free Survival; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Infusions, Intravenous; Living Donors; Male; Myeloablative Agonists; Prospective Studies; Rabbits; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2006 |
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Confidence Intervals; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine | 2000 |
29 other study(ies) available for vidarabine and Hematologic Diseases
| Article | Year |
|---|---|
[Cutaneous complications following hematopoietic stem cell transplantation].
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Candidiasis; Chickenpox; Child; Chronic Disease; Dermatomycoses; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Herpes Genitalis; Humans; Induction Chemotherapy; Malassezia; Male; Melphalan; Middle Aged; Morocco; Prospective Studies; Skin Diseases; Skin Diseases, Infectious; Vidarabine; Young Adult | 2021 |
Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.
Topics: Administration, Intravenous; Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Lung Diseases; Lymphocyte Depletion; Male; Middle Aged; Myeloablative Agonists; Respiratory Function Tests; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2014 |
A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Cord Blood Stem Cell Transplantation; Drug Interactions; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycoses; Premedication; Prospective Studies; Risk Factors; Transplantation Conditioning; Vidarabine; Voriconazole; Young Adult | 2014 |
[The outcome of thirteen patients with nonmalignant hematologic diseases treated with HLA haploidentical stem cell transplantation].
Topics: Anemia, Aplastic; Busulfan; Graft vs Host Disease; Hematologic Diseases; Histocompatibility; HLA Antigens; Humans; Incidence; Methotrexate; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Hematologic Diseases; Humans; Male; Melphalan; Middle Aged; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2015 |
Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.
Topics: Adolescent; Allografts; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Databases, Factual; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Quality of Health Care; Quality of Life; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2015 |
[Transplant-Related Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Busulfan-Based Reduced-Intensity Conditioning - A Retrospective Analysis in a Single Institution].
Topics: Adult; Aged; Allografts; Busulfan; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2015 |
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Pancytopenia; Prevalence; Retrospective Studies; Thrombocytopenia; Time Factors; Vidarabine | 2010 |
Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.
Topics: Adult; Aged; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2011 |
Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44.
Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Busulfan; CD3 Complex; Child; Down-Regulation; Female; Forkhead Transcription Factors; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hyaluronan Receptors; Immunosuppression Therapy; Interleukin-2 Receptor alpha Subunit; Interleukin-7 Receptor alpha Subunit; Leukocytes, Mononuclear; Lymphocyte Culture Test, Mixed; Male; Middle Aged; Myeloablative Agonists; Protein Binding; Rabbits; Radiation Tolerance; T-Lymphocytes, Regulatory; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Drug Administration Schedule; Female; Graft vs Host Reaction; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult | 2013 |
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Mitoxantrone; Radionuclide Imaging; Retrospective Studies; Treatment Outcome; Vidarabine | 2013 |
Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antineoplastic Agents; Dendritic Cells; Flow Cytometry; Fluorescent Antibody Technique; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes; Neoplasms; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation, Homologous; Vidarabine | 2002 |
Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarabine and anti-lymphocyte gamma-globulin.
Topics: Adolescent; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoiesis; Histocompatibility; Humans; Immunosuppressive Agents; Male; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce dura
Topics: Adult; Aged; Child; Cyclosporine; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Remission Induction; Survival Rate; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
Low-dose total-body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA-identical sibling donors do not induce complete T-cell donor engraftment in most patients with progressive hematologic diseases.
Topics: Adult; Aged; Cyclosporine; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Middle Aged; Myeloid Cells; Prospective Studies; T-Lymphocytes; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
[Seventeen cases of nonmyeloablative stem cell transplantation using a conditioning regimen containing fludarabine].
Topics: Adult; Female; Follow-Up Studies; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
[Comparison of conditioning regimens containing or no fludarabine in nonmyeloablative allogeneic peripheral blood stem cell transplantation].
Topics: Adolescent; Adult; Female; Follow-Up Studies; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
Topics: Adult; Aged; Antilymphocyte Serum; Bone Marrow Transplantation; Cladribine; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.
Topics: Antineoplastic Agents, Alkylating; Graft Rejection; Granulocyte Precursor Cells; Hematologic Diseases; Humans; Immunosuppressive Agents; Melphalan; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2004 |
Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases.
Topics: Adult; Aged; Blood Platelets; Cyclosporine; Feasibility Studies; Female; Fetal Blood; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neutrophils; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2004 |
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug Induced Liver Injury; Cholangitis; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Hematologic Diseases; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunosuppressive Agents; Incidence; Infant, Newborn; Liver Diseases; Liver Function Tests; Male; Melphalan; Middle Aged; Postoperative Complications; Risk Factors; Tacrolimus; Tissue Donors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Prognosis; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Topics: Adult; Aged; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Hematologic abnormalities associated with vidarabine.
Topics: Female; Hematologic Diseases; Herpes Simplex; Humans; Infant, Newborn; Vidarabine | 1984 |
Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience.
Topics: Anemia, Hemolytic, Autoimmune; Antimetabolites, Antineoplastic; Cause of Death; Drug Evaluation; Fever; Graft vs Host Disease; Hematologic Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Remission Induction; Retrospective Studies; Salvage Therapy; Spain; Survival Analysis; Transfusion Reaction; Treatment Outcome; Vidarabine | 1996 |
Role of splenectomy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Case-Control Studies; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Neoplasm Staging; Retrospective Studies; Splenectomy; Survival Analysis; Treatment Outcome; Vidarabine | 1997 |
Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infections; Infusion Pumps; Leukemia; Lung Diseases; Male; Middle Aged; Nervous System Diseases; Prognosis; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Vidarabine | 2001 |